402P - Adult medulloblastoma: An oncology radiation therapy department experience with 22 cases

Abstract

Listen

Translate article

Background: Medulloblastoma is the most common central nervous system tumor in children. However, the occurrence in adults is rare and accounts for about 1% - 2%. The objective of this study is to define the clinical characteristic of this entity and therapeutic results. Methods: We retrospectively evaluated the treatment data of 22 adult patients (≥18 years) treated for medulloblatoma from 1993 to 2013 in our department. Median follow up was 161.5 months [58; 296 months]. Results: Male female ratio was 2.14 :1. Median age was 25 years [18 ; 57]. Eight patients (36%) had cerebellar hemispheric tumors, nine cases (41%) occur in the vermis and five patients (23%) had an hemispheric-vermian localisation. Twenty one patients (95%) underwent macroscopically total exicision. Sixteen patients (73%) had classic form; five patients had desmoplastic (23%) type and one patient had extensive nodularity type. Patients were stratified into standard and high risk in 14 and 5 cases respectively. The risk couldn’t be identified for 3 patients. Among patients in the high-risk group, four received a cisplatin/etoposide chemotherapy before radiation. All patients had craniospinal radiotherapy. The mean interval between surgery and the begining of radiation therapy was 107 days. Craniospinal dose range between 30Gy and 36Gy. The dose in the posterior fossa was respectively 54Gy and 64Gy in 18 (82%) and 4 (18%) cases. The 5 year overall survival was 63%. Conclusions: There are differences between pediatric and adult patients with medulloblastoma in terms of clinical and pathological characteristic. Ultimately, prospective trials including adult patient with medulloblastoma are needed to optimize the management of this rare and complex disease. Legal entity responsible for the study: Kallel Mouna. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.